{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:08:17Z","timestamp":1785247697575,"version":"3.55.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008871","name":"Juvenile Diabetes Research Foundation United States of America","doi-asserted-by":"publisher","award":["5-CDA-2015-89-A-B"],"award-info":[{"award-number":["5-CDA-2015-89-A-B"]}],"id":[{"id":"10.13039\/100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK036836"],"award-info":[{"award-number":["P30 DK036836"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A substantial number of subjects with Type 1 Diabetes (T1D) of long duration never develop albuminuria or renal function impairment, yet the underlying protective mechanisms remain unknown. Therefore, our study included 308 Joslin Kidney Study subjects who had T1D of long duration (median: 24\u00a0years), maintained normal renal function and had either normoalbuminuria or a broad range of albuminuria within the 2\u00a0years preceding the metabolomic determinations. Serum samples were subjected to global metabolomic profiling. 352 metabolites were detected in at least 80% of the study population. In the logistic analyses adjusted for multiple testing (Bonferroni corrected \u03b1\u2009=\u20090.000028), we identified 38 metabolites associated with persistent normoalbuminuria independently from clinical covariates. Protective metabolites were enriched in Medium Chain Fatty Acids (MCFAs) and in Short Chain Fatty Acids (SCFAs) and particularly involved odd-numbered and dicarboxylate Fatty Acids. One quartile change of nonanoate, the top protective MCFA, was associated with high odds of having persistent normoalbuminuria (OR (95% CI) 0.14 (0.09, 0.23); p\u2009&lt;\u200910<jats:sup>\u201312<\/jats:sup>). Multivariable Random Forest analysis concordantly indicated to MCFAs as effective classifiers. Associations of the relevant Fatty Acids with albuminuria seemed to parallel associations with tubular biomarkers. Our findings suggest that MCFAs and SCFAs contribute to the metabolic processes underlying protection against albuminuria development in T1D that are independent from mechanisms associated with changes in renal function.<\/jats:p>","DOI":"10.1038\/s41598-021-87585-1","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T10:19:00Z","timestamp":1619000340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Circulating short and medium chain fatty acids are associated with normoalbuminuria in type 1 diabetes of long duration"],"prefix":"10.1038","volume":"11","author":[{"given":"Salina","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Tsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lampert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaipul I.","family":"Md Dom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar D.","family":"Kostic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Smiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika A.","family":"Niewczas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"87585_CR1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1681\/asn.2010040354","volume":"22","author":"ET Rosolowsky","year":"2011","unstructured":"Rosolowsky, E. T. et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J. Am. Soc. Nephrol. 22, 545\u2013553. https:\/\/doi.org\/10.1681\/asn.2010040354 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87585_CR2","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.2215\/cjn.02870316","volume":"11","author":"IH de Boer","year":"2016","unstructured":"de Boer, I. H. et al. Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: The DCCT\/EDIC study. Clin. J. Am. Soc. Nephrol. 11, 1969\u20131977. https:\/\/doi.org\/10.2215\/cjn.02870316 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"87585_CR3","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1681\/ASN.V76930","volume":"7","author":"JH Warram","year":"1996","unstructured":"Warram, J. H., Gearin, G., Laffel, L. & Krolewski, A. S. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin\/creatinine ratio. J. Am. Soc. Nephrol. 7, 930\u2013937 (1996).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87585_CR4","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1056\/NEJMoa021835","volume":"348","author":"BA Perkins","year":"2003","unstructured":"Perkins, B. A. et al. Regression of microalbuminuria in type 1 diabetes. N. Engl. J. Med. 348, 2285\u20132293. https:\/\/doi.org\/10.1056\/NEJMoa021835 (2003).","journal-title":"N. Engl. J. Med."},{"key":"87585_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/bf00284458","volume":"25","author":"AR Andersen","year":"1983","unstructured":"Andersen, A. R. et al. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study. Diabetologia 25, 496\u2013501. https:\/\/doi.org\/10.1007\/bf00284458 (1983).","journal-title":"Diabetologia"},{"key":"87585_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/0002-9343(85)90284-0","volume":"78","author":"AS Krolewski","year":"1985","unstructured":"Krolewski, A. S. et al. The changing natural history of nephropathy in type I diabetes. Am. J. Med. 78, 785\u2013794. https:\/\/doi.org\/10.1016\/0002-9343(85)90284-0 (1985).","journal-title":"Am. J. Med."},{"key":"87585_CR7","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1056\/nejm198711263172206","volume":"317","author":"AS Krolewski","year":"1987","unstructured":"Krolewski, A. S., Warram, J. H., Rand, L. I. & Kahn, C. R. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N. Engl. J. Med. 317, 1390\u20131398. https:\/\/doi.org\/10.1056\/nejm198711263172206 (1987).","journal-title":"N. Engl. J. Med."},{"key":"87585_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semnephrol.2018.02.001","volume":"38","author":"K Sharma","year":"2018","unstructured":"Sharma, K., Susztak, K. & Pennathur, S. Introduction: Systems biology of kidney disease. Semin. Nephrol. 38, 99\u2013100. https:\/\/doi.org\/10.1016\/j.semnephrol.2018.02.001 (2018).","journal-title":"Semin. Nephrol."},{"key":"87585_CR9","doi-asserted-by":"publisher","first-page":"718","DOI":"10.2337\/db14-0509,PMC4338589","volume":"64","author":"KM Sas","year":"2015","unstructured":"Sas, K. M., Karnovsky, A., Michailidis, G. & Pennathur, S. Metabolomics and diabetes: Analytical and computational approaches. Diabetes 64, 718\u2013732. https:\/\/doi.org\/10.2337\/db14-0509,PMC4338589 (2015).","journal-title":"Diabetes"},{"key":"87585_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2337\/dc16-0173,PMC5319475","volume":"40","author":"MA Niewczas","year":"2017","unstructured":"Niewczas, M. A. et al. Circulating modified metabolites and a risk of ESRD in patients with type 1 diabetes and chronic kidney disease. Diabetes Care 40, 383\u2013390. https:\/\/doi.org\/10.2337\/dc16-0173,PMC5319475 (2017).","journal-title":"Diabetes Care"},{"key":"87585_CR11","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/ki.2013.497,PMC4072128","volume":"85","author":"MA Niewczas","year":"2014","unstructured":"Niewczas, M. A. et al. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: Metabolomic study. Kidney Int. 85, 1214\u20131224. https:\/\/doi.org\/10.1038\/ki.2013.497,PMC4072128 (2014).","journal-title":"Kidney Int."},{"key":"87585_CR12","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1093\/bioinformatics\/btz114,PMC6748777","volume":"35","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. Differential network enrichment analysis reveals novel lipid pathways in chronic kidney disease. Bioinformatics 35, 3441\u20133452. https:\/\/doi.org\/10.1093\/bioinformatics\/btz114,PMC6748777 (2019).","journal-title":"Bioinformatics"},{"key":"87585_CR13","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1210\/jc.2015-3345","volume":"101","author":"A Solini","year":"2016","unstructured":"Solini, A. et al. Prediction of declining renal function and albuminuria in patients with type 2 diabetes by metabolomics. J. Clin. Endocrinol. Metab. 101, 696\u2013704. https:\/\/doi.org\/10.1210\/jc.2015-3345 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"87585_CR14","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1681\/asn.2012101006,PMC3736702","volume":"24","author":"EP Rhee","year":"2013","unstructured":"Rhee, E. P. et al. A combined epidemiologic and metabolomic approach improves CKD prediction. J. Am. Soc. Nephrol. 24, 1330\u20131338. https:\/\/doi.org\/10.1681\/asn.2012101006,PMC3736702 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87585_CR15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3389\/fendo.2019.00818","volume":"10","author":"N Tofte","year":"2019","unstructured":"Tofte, N. et al. Metabolomic assessment reveals alteration in polyols and branched chain amino acids associated with present and future renal impairment in a discovery cohort of 637 persons with type 1 diabetes. Front. Endocrinol. 10, 818. https:\/\/doi.org\/10.3389\/fendo.2019.00818 (2019).","journal-title":"Front. Endocrinol."},{"key":"87585_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11306-018-1380-6","volume":"14","author":"PJ Saulnier","year":"2018","unstructured":"Saulnier, P. J. et al. Urine metabolites are associated with glomerular lesions in type 2 diabetes. Metabolomics 14, 84. https:\/\/doi.org\/10.1007\/s11306-018-1380-6 (2018).","journal-title":"Metabolomics"},{"key":"87585_CR17","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1681\/asn.2011121175","volume":"23","author":"F Duranton","year":"2012","unstructured":"Duranton, F. et al. Normal and pathologic concentrations of uremic toxins. J. Am. Soc. Nephrol. 23, 1258\u20131270. https:\/\/doi.org\/10.1681\/asn.2011121175 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87585_CR18","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1681\/asn.2009111132","volume":"21","author":"EP Rhee","year":"2010","unstructured":"Rhee, E. P. et al. Metabolite profiling identifies markers of uremia. J. Am. Soc. Nephrol. 21, 1041\u20131051. https:\/\/doi.org\/10.1681\/asn.2009111132 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87585_CR19","doi-asserted-by":"publisher","first-page":"F157","DOI":"10.1152\/ajprenal.00443.2011","volume":"303","author":"T Gohda","year":"2012","unstructured":"Gohda, T. et al. Elevated urinary excretion of immunoglobulins in nonproteinuric patients with type 1 diabetes. Am. J. Physiol. Renal Physiol. 303, F157\u2013F162. https:\/\/doi.org\/10.1152\/ajprenal.00443.2011 (2012).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"87585_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/ki.2010.404","volume":"79","author":"VS Vaidya","year":"2011","unstructured":"Vaidya, V. S. et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-\u03b2-D-glucosaminidase. Kidney Int. 79, 464\u2013470. https:\/\/doi.org\/10.1038\/ki.2010.404 (2011).","journal-title":"Kidney Int."},{"key":"87585_CR21","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1681\/asn.2007050556","volume":"19","author":"PP Wolkow","year":"2008","unstructured":"Wolkow, P. P. et al. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J. Am. Soc. Nephrol. 19, 789\u2013797. https:\/\/doi.org\/10.1681\/asn.2007050556 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87585_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/ki.2015.314","volume":"89","author":"N Nowak","year":"2016","unstructured":"Nowak, N. et al. Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. Kidney Int. 89, 459\u2013467. https:\/\/doi.org\/10.1038\/ki.2015.314 (2016).","journal-title":"Kidney Int."},{"key":"87585_CR23","doi-asserted-by":"publisher","first-page":"13853","DOI":"10.1038\/s41598-018-32085-y","volume":"8","author":"JK Haukka","year":"2018","unstructured":"Haukka, J. K. et al. Metabolomic profile predicts development of microalbuminuria in individuals with type 1 diabetes. Sci. Rep. 8, 13853. https:\/\/doi.org\/10.1038\/s41598-018-32085-y (2018).","journal-title":"Sci. Rep."},{"key":"87585_CR24","doi-asserted-by":"publisher","first-page":"e13953","DOI":"10.1371\/journal.pone.0013953","volume":"5","author":"K Suhre","year":"2010","unstructured":"Suhre, K. et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 5, e13953. https:\/\/doi.org\/10.1371\/journal.pone.0013953 (2010).","journal-title":"PLoS ONE"},{"key":"87585_CR25","doi-asserted-by":"publisher","first-page":"5398","DOI":"10.7150\/thno.41725","volume":"10","author":"IW Wu","year":"2020","unstructured":"Wu, I. W. et al. Integrative metagenomic and metabolomic analyses reveal severity-specific signatures of gut microbiota in chronic kidney disease. Theranostics 10, 5398\u20135411. https:\/\/doi.org\/10.7150\/thno.41725 (2020).","journal-title":"Theranostics"},{"key":"87585_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5551\/jat.42945","volume":"26","author":"K Omori","year":"2019","unstructured":"Omori, K. et al. Identification of metabolites associated with onset of CAD in diabetic patients using CE-MS analysis: A pilot study. J. Atheroscler. Thromb. 26, 233\u2013245. https:\/\/doi.org\/10.5551\/jat.42945 (2019).","journal-title":"J. Atheroscler. Thromb."},{"key":"87585_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1210\/jc.2015-3292","volume":"101","author":"S Airhart","year":"2016","unstructured":"Airhart, S. et al. A diet rich in medium-chain fatty acids improves systolic function and alters the lipidomic profile in patients with type 2 diabetes: A pilot study. J. Clin. Endocrinol. Metab. 101, 504\u2013512. https:\/\/doi.org\/10.1210\/jc.2015-3292 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"87585_CR28","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/s0024-3205(97)01143-0","volume":"62","author":"AA Papamandjaris","year":"1998","unstructured":"Papamandjaris, A. A., MacDougall, D. E. & Jones, P. J. Medium chain fatty acid metabolism and energy expenditure: Obesity treatment implications. Life Sci. 62, 1203\u20131215. https:\/\/doi.org\/10.1016\/s0024-3205(97)01143-0 (1998).","journal-title":"Life Sci."},{"key":"87585_CR29","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000446484","volume":"43","author":"EP Rhee","year":"2016","unstructured":"Rhee, E. P. et al. Metabolomics of chronic kidney disease progression: A case-control analysis in the chronic renal insufficiency cohort study. Am. J. Nephrol. 43, 366\u2013374. https:\/\/doi.org\/10.1159\/000446484 (2016).","journal-title":"Am. J. Nephrol."},{"key":"87585_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/antibiotics9020075","volume":"9","author":"CL Fischer","year":"2020","unstructured":"Fischer, C. L. Antimicrobial activity of host-derived lipids. Antibiotics 9, 75. https:\/\/doi.org\/10.3390\/antibiotics9020075 (2020).","journal-title":"Antibiotics"},{"key":"87585_CR31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41564-018-0306-4","volume":"4","author":"EA Franzosa","year":"2019","unstructured":"Franzosa, E. A. et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat. Microbiol. 4, 293\u2013305. https:\/\/doi.org\/10.1038\/s41564-018-0306-4 (2019).","journal-title":"Nat. Microbiol."},{"key":"87585_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10557-008-6084-0","volume":"22","author":"F Labarthe","year":"2008","unstructured":"Labarthe, F., G\u00e9linas, R. & Des Rosiers, C. Medium-chain fatty acids as metabolic therapy in cardiac disease. Cardiovasc. Drugs Ther. 22, 97\u2013106. https:\/\/doi.org\/10.1007\/s10557-008-6084-0 (2008).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"87585_CR33","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/s2213-8587(14)70146-9","volume":"2","author":"NG Forouhi","year":"2014","unstructured":"Forouhi, N. G. et al. Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: The EPIC-InterAct case-cohort study. Lancet Diabetes Endocrinol. 2, 810\u2013818. https:\/\/doi.org\/10.1016\/s2213-8587(14)70146-9 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"87585_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ajcn\/69.1.22","volume":"69","author":"AE Smedman","year":"1999","unstructured":"Smedman, A. E., Gustafsson, I. B., Berglund, L. G. & Vessby, B. O. Pentadecanoic acid in serum as a marker for intake of milk fat: Relations between intake of milk fat and metabolic risk factors. Am. J. Clin. Nutr. 69, 22\u201329. https:\/\/doi.org\/10.1093\/ajcn\/69.1.22 (1999).","journal-title":"Am. J. Clin. Nutr."},{"key":"87585_CR35","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/ajcn\/86.4.929","volume":"86","author":"Q Sun","year":"2007","unstructured":"Sun, Q., Ma, J., Campos, H. & Hu, F. B. Plasma and erythrocyte biomarkers of dairy fat intake and risk of ischemic heart disease. Am. J. Clin. Nutr. 86, 929\u2013937. https:\/\/doi.org\/10.1093\/ajcn\/86.4.929 (2007).","journal-title":"Am. J. Clin. Nutr."},{"key":"87585_CR36","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1038\/sj.ejcn.1602256","volume":"59","author":"A Brevik","year":"2005","unstructured":"Brevik, A., Veier\u00f8d, M. B., Drevon, C. A. & Andersen, L. F. Evaluation of the odd fatty acids 15:0 and 17:0 in serum and adipose tissue as markers of intake of milk and dairy fat. Eur. J. Clin. Nutr. 59, 1417\u20131422. https:\/\/doi.org\/10.1038\/sj.ejcn.1602256 (2005).","journal-title":"Eur. J. Clin. Nutr."},{"key":"87585_CR37","doi-asserted-by":"publisher","first-page":"e1001255","DOI":"10.1371\/journal.pmed.1001255","volume":"9","author":"KT Khaw","year":"2012","unstructured":"Khaw, K. T. et al. Plasma phospholipid fatty acid concentration and incident coronary heart disease in men and women: The EPIC-Norfolk prospective study. PLoS Med. 9, e1001255. https:\/\/doi.org\/10.1371\/journal.pmed.1001255 (2012).","journal-title":"PLoS Med."},{"key":"87585_CR38","unstructured":"U.S. Department of Agriculture & Agricultural Research Service. FoodData Central, 2019. fdc.nal.usda.gov. Accessed 25 Sept 2020."},{"key":"87585_CR39","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1161\/circulationaha.119.043052","volume":"141","author":"N Neelakantan","year":"2020","unstructured":"Neelakantan, N., Seah, J. Y. H. & van Dam, R. M. The effect of coconut oil consumption on cardiovascular risk factors: A systematic review and meta-analysis of clinical trials. Circulation 141, 803\u2013814. https:\/\/doi.org\/10.1161\/circulationaha.119.043052 (2020).","journal-title":"Circulation"},{"key":"87585_CR40","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1194\/jlr.R067629","volume":"57","author":"P Sch\u00f6nfeld","year":"2016","unstructured":"Sch\u00f6nfeld, P. & Wojtczak, L. Short- and medium-chain fatty acids in energy metabolism: The cellular perspective. J. Lipid Res. 57, 943\u2013954. https:\/\/doi.org\/10.1194\/jlr.R067629 (2016).","journal-title":"J. Lipid Res."},{"key":"87585_CR41","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/j.1365-2125.2012.04177.x","volume":"75","author":"G Mingrone","year":"2013","unstructured":"Mingrone, G., Castagneto-Gissey, L. & Mac\u00e9, K. Use of dicarboxylic acids in type 2 diabetes. Br. J. Clin. Pharmacol. 75, 671\u2013676. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04177.x (2013).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"87585_CR42","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s0899-9007(97)00502-9","volume":"14","author":"AV Greco","year":"1998","unstructured":"Greco, A. V. et al. The metabolic effect of dodecanedioic acid infusion in non-insulin-dependent diabetic patients. Nutrition 14, 351\u2013357. https:\/\/doi.org\/10.1016\/s0899-9007(97)00502-9 (1998).","journal-title":"Nutrition"},{"key":"87585_CR43","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.2337\/dc10-0663","volume":"33","author":"A Iaconelli","year":"2010","unstructured":"Iaconelli, A. et al. Effect of oral sebacic Acid on postprandial glycemia, insulinemia, and glucose rate of appearance in type 2 diabetes. Diabetes Care 33, 2327\u20132332. https:\/\/doi.org\/10.2337\/dc10-0663 (2010).","journal-title":"Diabetes Care"},{"key":"87585_CR44","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/dom.14018","volume":"22","author":"S Mulder","year":"2020","unstructured":"Mulder, S. et al. A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes. Diabetes Obes. Metab. 22, 1157\u20131166. https:\/\/doi.org\/10.1111\/dom.14018 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"87585_CR45","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s13668-018-0248-8","volume":"7","author":"ES Chambers","year":"2018","unstructured":"Chambers, E. S., Preston, T., Frost, G. & Morrison, D. J. Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health. Curr. Nutr. Rep. 7, 198\u2013206. https:\/\/doi.org\/10.1007\/s13668-018-0248-8 (2018).","journal-title":"Curr. Nutr. Rep."},{"key":"87585_CR46","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1136\/gutjnl-2014-307913","volume":"64","author":"ES Chambers","year":"2015","unstructured":"Chambers, E. S. et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut 64, 1744\u20131754. https:\/\/doi.org\/10.1136\/gutjnl-2014-307913 (2015).","journal-title":"Gut"},{"key":"87585_CR47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/dom.12811","volume":"19","author":"A Pingitore","year":"2017","unstructured":"Pingitore, A. et al. The diet-derived short chain fatty acid propionate improves beta-cell function in humans and stimulates insulin secretion from human islets in vitro. Diabetes Obes. Metab. 19, 257\u2013265. https:\/\/doi.org\/10.1111\/dom.12811 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"87585_CR48","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.nut.2015.08.006","volume":"32","author":"C Vetrani","year":"2016","unstructured":"Vetrani, C. et al. Effects of whole-grain cereal foods on plasma short chain fatty acid concentrations in individuals with the metabolic syndrome. Nutrition 32, 217\u2013221. https:\/\/doi.org\/10.1016\/j.nut.2015.08.006 (2016).","journal-title":"Nutrition"},{"key":"87585_CR49","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1055\/s-0043-119089","volume":"49","author":"N Roshanravan","year":"2017","unstructured":"Roshanravan, N. et al. Effect of butyrate and inulin supplementation on glycemic status, lipid profile and glucagon-like peptide 1 level in patients with type 2 diabetes: A randomized double-blind, Placebo-controlled trial. Horm. Metab. Res. 49, 886\u2013891. https:\/\/doi.org\/10.1055\/s-0043-119089 (2017).","journal-title":"Horm. Metab. Res."},{"key":"87585_CR50","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1042\/cs20160263","volume":"130","author":"CM van der Beek","year":"2016","unstructured":"van der Beek, C. M. et al. Distal, not proximal, colonic acetate infusions promote fat oxidation and improve metabolic markers in overweight\/obese men. Clin. Sci. 130, 2073\u20132082. https:\/\/doi.org\/10.1042\/cs20160263 (2016).","journal-title":"Clin. Sci."},{"key":"87585_CR51","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1038\/s41598-017-02546-x","volume":"7","author":"EE Canfora","year":"2017","unstructured":"Canfora, E. E. et al. Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight\/obese men: A randomized crossover trial. Sci. Rep. 7, 2360. https:\/\/doi.org\/10.1038\/s41598-017-02546-x (2017).","journal-title":"Sci. Rep."},{"key":"87585_CR52","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1113\/jp272613","volume":"595","author":"E Boets","year":"2017","unstructured":"Boets, E. et al. Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study. J. Physiol. 595, 541\u2013555. https:\/\/doi.org\/10.1113\/jp272613 (2017).","journal-title":"J. Physiol."},{"key":"87585_CR53","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1038\/s41467-018-07563-6","volume":"9","author":"S Knorr","year":"2018","unstructured":"Knorr, S. et al. Widespread bacterial lysine degradation proceeding via glutarate and L-2-hydroxyglutarate. Nat. Commun. 9, 5071. https:\/\/doi.org\/10.1038\/s41467-018-07563-6 (2018).","journal-title":"Nat. Commun."},{"key":"87585_CR54","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1039\/c7mb00167c","volume":"13","author":"L Li","year":"2017","unstructured":"Li, L. et al. Metabolomics reveal mitochondrial and fatty acid metabolism disorders that contribute to the development of DKD in T2DM patients. Mol. Biosyst. 13, 2392\u20132400. https:\/\/doi.org\/10.1039\/c7mb00167c (2017).","journal-title":"Mol. Biosyst."},{"key":"87585_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-0433-9","author":"Y Fan","year":"2020","unstructured":"Fan, Y. & Pedersen, O. Gut microbiota in human metabolic health and disease. Nat. Rev. Microbiol. https:\/\/doi.org\/10.1038\/s41579-020-0433-9 (2020).","journal-title":"Nat. Rev. Microbiol."},{"key":"87585_CR56","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2016.10924","volume":"316","author":"M Afkarian","year":"2016","unstructured":"Afkarian, M. et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988\u20132014. JAMA 316, 602\u2013610. https:\/\/doi.org\/10.1001\/jama.2016.10924 (2016).","journal-title":"JAMA"},{"key":"87585_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 3, 1\u2013150 (2013).","journal-title":"Kidney Int."},{"key":"87585_CR58","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1681\/asn.2014111099","volume":"27","author":"P Sekula","year":"2016","unstructured":"Sekula, P. et al. A metabolome-wide association study of kidney function and disease in the general population. J. Am. Soc. Nephrol. 27, 1175\u20131188. https:\/\/doi.org\/10.1681\/asn.2014111099 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"87585_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa175","author":"ML Manca","year":"2020","unstructured":"Manca, M. L. et al. Differential metabolomic signatures of declining renal function in types 1 and 2 diabetes. Nephrol. Dial. Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaa175 (2020).","journal-title":"Nephrol. Dial. Transplant."},{"key":"87585_CR60","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.redox.2012.12.001","volume":"1","author":"G Poli","year":"2013","unstructured":"Poli, G., Biasi, F. & Leonarduzzi, G. Oxysterols in the pathogenesis of major chronic diseases. Redox Biol. 1, 125\u2013130. https:\/\/doi.org\/10.1016\/j.redox.2012.12.001 (2013).","journal-title":"Redox Biol."},{"key":"87585_CR61","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.2337\/db13-0399","volume":"62","author":"S Merscher-Gomez","year":"2013","unstructured":"Merscher-Gomez, S. et al. Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes 62, 3817\u20133827. https:\/\/doi.org\/10.2337\/db13-0399 (2013).","journal-title":"Diabetes"},{"key":"87585_CR62","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1021\/pr201036j","volume":"11","author":"VP M\u00e4kinen","year":"2012","unstructured":"M\u00e4kinen, V. P. et al. Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study). J. Proteome Res. 11, 1782\u20131790. https:\/\/doi.org\/10.1021\/pr201036j (2012).","journal-title":"J. Proteome Res."},{"key":"87585_CR63","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.metabol.2014.07.001","volume":"63","author":"RL Klein","year":"2014","unstructured":"Klein, R. L. et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism 63, 1287\u20131295. https:\/\/doi.org\/10.1016\/j.metabol.2014.07.001 (2014).","journal-title":"Metabolism"},{"key":"87585_CR64","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1007\/s00125-019-4915-0","volume":"62","author":"M Colombo","year":"2019","unstructured":"Colombo, M. et al. Biomarker panels associated with progression of renal disease in type 1 diabetes. Diabetologia 62, 1616\u20131627. https:\/\/doi.org\/10.1007\/s00125-019-4915-0 (2019).","journal-title":"Diabetologia"},{"key":"87585_CR65","doi-asserted-by":"publisher","first-page":"F150","DOI":"10.1152\/ajprenal.00246.2011","volume":"302","author":"YM Hu","year":"2012","unstructured":"Hu, Y. M. et al. Glutamine administration ameliorates sepsis-induced kidney injury by downregulating the high-mobility group box protein-1-mediated pathway in mice. Am. J. Physiol. Renal Physiol. 302, F150\u2013F158. https:\/\/doi.org\/10.1152\/ajprenal.00246.2011 (2012).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"87585_CR66","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jphs.2014.11.009","volume":"127","author":"HJ Kim","year":"2015","unstructured":"Kim, H. J. et al. Glutamine protects against cisplatin-induced nephrotoxicity by decreasing cisplatin accumulation. J. Pharmacol. Sci. 127, 117\u2013126. https:\/\/doi.org\/10.1016\/j.jphs.2014.11.009 (2015).","journal-title":"J. Pharmacol. Sci."},{"key":"87585_CR67","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/dme.12447","volume":"31","author":"MJ Pena","year":"2014","unstructured":"Pena, M. J. et al. Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. Diabet. Med. 31, 1138\u20131147. https:\/\/doi.org\/10.1111\/dme.12447 (2014).","journal-title":"Diabet. Med."},{"key":"87585_CR68","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/aje\/kwx167","volume":"186","author":"CM Rebholz","year":"2017","unstructured":"Rebholz, C. M. et al. Serum levels of 1,5-anhydroglucitol and risk of incident end-stage renal disease. Am. J. Epidemiol. 186, 952\u2013960. https:\/\/doi.org\/10.1093\/aje\/kwx167 (2017).","journal-title":"Am. J. Epidemiol."},{"key":"87585_CR69","doi-asserted-by":"publisher","first-page":"960","DOI":"10.2337\/dc10-1945","volume":"34","author":"E Selvin","year":"2011","unstructured":"Selvin, E. et al. Nontraditional markers of glycemia: Associations with microvascular conditions. Diabetes Care 34, 960\u2013967. https:\/\/doi.org\/10.2337\/dc10-1945 (2011).","journal-title":"Diabetes Care"},{"key":"87585_CR70","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1373\/clinchem.2014.229427","volume":"60","author":"E Selvin","year":"2014","unstructured":"Selvin, E. et al. Association of 1,5-anhydroglucitol with diabetes and microvascular conditions. Clin. Chem. 60, 1409\u20131418. https:\/\/doi.org\/10.1373\/clinchem.2014.229427 (2014).","journal-title":"Clin. Chem."},{"key":"87585_CR71","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nm.3762","volume":"21","author":"HM Kang","year":"2015","unstructured":"Kang, H. M. et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat. Med. 21, 37\u201346. https:\/\/doi.org\/10.1038\/nm.3762 (2015).","journal-title":"Nat. Med."},{"key":"87585_CR72","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1371\/journal.pmed.0020045","volume":"2","author":"K Susztak","year":"2005","unstructured":"Susztak, K. et al. Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med. 2, e45. https:\/\/doi.org\/10.1371\/journal.pmed.0020045 (2005).","journal-title":"PLoS Med."},{"key":"87585_CR73","doi-asserted-by":"publisher","first-page":"968","DOI":"10.2337\/dc10-1675","volume":"34","author":"JK Sun","year":"2011","unstructured":"Sun, J. K. et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: The Joslin 50-year Medalist study. Diabetes Care 34, 968\u2013974. https:\/\/doi.org\/10.2337\/dc10-1675 (2011).","journal-title":"Diabetes Care"},{"key":"87585_CR74","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2337\/dci17-0047","volume":"41","author":"GL Bakris","year":"2018","unstructured":"Bakris, G. L. & Molitch, M. Are all patients with type 1 diabetes destined for dialysis if they live long enough? Probably not. Diabetes Care 41, 389\u2013390. https:\/\/doi.org\/10.2337\/dci17-0047 (2018).","journal-title":"Diabetes Care"},{"key":"87585_CR75","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2337\/dc17-1118,PMC5829956","volume":"41","author":"T Costacou","year":"2018","unstructured":"Costacou, T. & Orchard, T. J. Cumulative kidney complication risk by 50 years of type 1 diabetes: The effects of sex, age, and calendar year at onset. Diabetes Care 41, 426\u2013433. https:\/\/doi.org\/10.2337\/dc17-1118,PMC5829956 (2018).","journal-title":"Diabetes Care"},{"key":"87585_CR76","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1001\/jama.294.14.1782","volume":"294","author":"P Finne","year":"2005","unstructured":"Finne, P. et al. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 294, 1782\u20131787. https:\/\/doi.org\/10.1001\/jama.294.14.1782 (2005).","journal-title":"JAMA"},{"key":"87585_CR77","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1214\/ss\/1009213726","volume":"16","author":"L Breiman","year":"2001","unstructured":"Breiman, L. Statistical modeling: The two cultures. Stat. Sci. 16, 199\u2013215 (2001).","journal-title":"Stat. Sci."},{"key":"87585_CR78","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/ki.2012.189","volume":"82","author":"J Skupien","year":"2012","unstructured":"Skupien, J. et al. The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int. 82, 589\u2013597. https:\/\/doi.org\/10.1038\/ki.2012.189 (2012).","journal-title":"Kidney Int."},{"key":"87585_CR79","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2337\/dc13-0985","volume":"37","author":"AS Krolewski","year":"2014","unstructured":"Krolewski, A. S. et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care 37, 226\u2013234. https:\/\/doi.org\/10.2337\/dc13-0985 (2014).","journal-title":"Diabetes Care"},{"key":"87585_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.07.007","author":"K Ihara","year":"2020","unstructured":"Ihara, K. et al. A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in type 1 diabetes is similar to profiles in autoimmune disorders. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2020.07.007 (2020).","journal-title":"Kidney Int."},{"key":"87585_CR81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1758-2946-2-9","volume":"2","author":"CD Dehaven","year":"2010","unstructured":"Dehaven, C. D., Evans, A. M., Dai, H. & Lawton, K. A. Organization of GC\/MS and LC\/MS metabolomics data into chemical libraries. J. Cheminform. 2, 9. https:\/\/doi.org\/10.1186\/1758-2946-2-9 (2010).","journal-title":"J. Cheminform."},{"key":"87585_CR82","unstructured":"Okabe, M. & Ito, K. Color Universal Design (CUD): How to make figures and presentations that are friendly to Colorblind people. Jfly, University of Tokyo. http:\/\/jfly.iam.u-tokyo.ac.jp\/color\/. Accessed 15 Dec 2020."},{"key":"87585_CR83","first-page":"18","volume":"2","author":"A Liaw","year":"2002","unstructured":"Liaw, A. & Wiener, M. Classification and regression by randomForest. R News 2, 18\u201322 (2002).","journal-title":"R News"},{"key":"87585_CR84","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer-Verlag, 2016). https:\/\/ggplot2.tidyverse.org. Accessed 22 Sept 2020.","DOI":"10.1007\/978-3-319-24277-4"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87585-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87585-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87585-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T06:55:14Z","timestamp":1670050514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87585-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["87585"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-87585-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]},"assertion":[{"value":"15 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8592"}}